Anzeige
Mehr »
Donnerstag, 15.05.2025 - Börsentäglich über 12.000 News
Verpasst du gerade die Buffett-Aktie der neuen Generation?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1W15D | ISIN: US00182C1036 | Ticker-Symbol: BSFA
Tradegate
15.05.25 | 16:48
54,00 Euro
-0,92 % -0,50
1-Jahres-Chart
ANI PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
ANI PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
53,5054,5019:29
53,5054,5019:11

Aktuelle News zur ANI PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrCortrophin Demand Is Soaring For ANI Pharma, CEO Says Well-Positioned To Mitigate Potential Tariff Impact1
FrANI Pharmaceuticals raises 2025 revenue guidance to $768M-$793M with 25%-29% growth1
FrANI Pharma Q1 Profit Down, Revenues Rise; Raises FY25 Outlook; Stock Up In Pre-market - Update1
FrANI Pharmaceuticals, Inc. Q1 Profit Decreases, But Beats Estimates225WASHINGTON (dpa-AFX) - ANI Pharmaceuticals, Inc. (ANIP) reported earnings for first quarter that decreased from the same period last year but beat the Street estimates.The company's bottom line...
► Artikel lesen
FrANI Pharmaceuticals Non-GAAP EPS of $1.70 beats by $0.32, revenue of $197.12M beats by $16.43M4
FrANI PHARMACEUTICALS INC - 10-Q, Quarterly Report1
ANI PHARMACEUTICALS Aktie jetzt für 0€ handeln
FrANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Raises 2025 Guidance963Generated record quarterly net revenues of $197.1 million, representing year-over-year growth of 43.4%Total Rare Disease quarterly net revenues of $69.0 million, which includes:Purified Cortrophin®...
► Artikel lesen
08.05.ANI Pharmaceuticals Q1 2025 Earnings Preview2
08.05.ANI PHARMACEUTICALS INC - 8-K, Current Report1
05.05.ANI Pharmaceuticals to Report Q1 Earnings: Is a Beat in the Cards?2
23.04.Buy 4 Low-Beta Stocks ANIP, LRN, MASS & CTGO as Tariff Woes Continue2
21.04.Truist raises ANI Pharmaceuticals target to $65, maintains hold7
12.04.Deep Dive Into ANI Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)3
09.04.ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET3
07.04.Tariff Woes? Play Safe With 4 Low-Beta Stocks: ANIP, EXE, AVA & CTGO1
19.03.ANI Pharmaceuticals Launches Nitazoxanide Tablets 500 Mg270WASHINGTON (dpa-AFX) - ANI Pharmaceuticals, Inc. (ANIP), Wednesday announced the launch of Nitazoxanide Tablets, 500 mg that are the generic version of the reference listed drug Alinia.Nikhil...
► Artikel lesen
19.03.ANI Pharmaceuticals launches generic Nitazoxanide Tablets3
19.03.ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Announces the Launch of Nitazoxanide Tablets132PRINCETON, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Nitazoxanide Tablets, 500 mg. ANI's Nitazoxanide Tablets...
► Artikel lesen
19.03.ANI Pharmaceuticals Eliminates Royalty Obligation On ILUVIEN And YUTIQ376WASHINGTON (dpa-AFX) - ANI Pharmaceuticals, Inc. (ANIP) Tuesday has completed the buyout of its 3.125 percent perpetual royalty obligation to SWK Funding LLC on global net revenues of ILUVIEN...
► Artikel lesen
18.03.ANI Pharma buys royalties linked to Iluvien and Yutiq2
Seite:  Weiter >>
71 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1